Skip to main content
RHHBY
OTC Life Sciences

Gazyva Wins First-Ever FDA Approval for Primary Membranous Nephropathy

Tom Rudovsky · Reported by BusinessWire
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$60.3
Mkt Cap
$384.639B
52W Low
$44.57
52W High
$61.75
52W Position info
35% above low
Off High info
2.3% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

RHHBY sits 35% above its 52-week low of $44.57 on light trading volume (0.4× avg).

Summary

The FDA approved Gazyva (obinutuzumab) for adults with primary membranous nephropathy at risk of progression, making it the first and only approved therapy for the disease. The decision rests on the Phase III MAJESTY trial, where 36.1% of patients on Gazyva hit complete remission of proteinuria at two years versus 5.7% on tacrolimus. This is Gazyva's third FDA approval in immune-mediated kidney disease, after idiopathic nephrotic syndrome and lupus nephritis, and it extends the franchise into a rare disease with an estimated US incidence of 1.2 per 100,000 people per year. The label expansion is incremental revenue for a company of Roche's size, but it reinforces Genentech's kidney-disease franchise and follows a run of positive regulatory news including the October Enspryng approval in thyroid eye disease. The FDA is also reviewing Gazyva for systemic lupus erythematosus with a decision expected by December 2026, and CHMP recently backed the SLE indication in Europe.

At the time of this announcement, RHHBY was trading at $60.30 on OTC in the Life Sciences sector, with a market capitalization of approximately $384.6B. The 52-week trading range was $44.57 to $61.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

RHHBY - Latest Insights

RHHBY
Oct 25, 2026, 11:30 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $61.17
Real-time Price: $60.30 info
Change: -$0.870 (-1%) info
Market Cap: $384.639B info
RHHBY
Oct 23, 2026, 1:30 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $60.19
Real-time Price: $60.30 info
Change: +$0.110 (+0.18%) info
Market Cap: $384.639B info
RHHBY
Oct 22, 2026, 12:50 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $59.48
Real-time Price: $60.30 info
Change: +$0.820 (+1%) info
Market Cap: $384.639B info
RHHBY
Oct 16, 2026, 1:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $56.78
Real-time Price: $60.30 info
Change: +$3.52 (+6%) info
Market Cap: $384.639B info
RHHBY
Oct 10, 2026, 5:40 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $54.09
Real-time Price: $60.30 info
Change: +$6.21 (+11%) info
Market Cap: $384.639B info